publication venue for
- Comparative safety and cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in nursing homes.. 26:3403-3417. 2024
- Effects of dipeptidyl peptidase-4 inhibitors and sulphonylureas on cognitive and physical function in nursing home residents.. 24:247-256. 2021
- Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin.. 23:2402-2408. 2021
- Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial.. 23:561-568. 2020
- Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study.. 23:39-48. 2020
- Trial design and baseline data for LIRA-PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care setting.. 21:1543-1550. 2019
- Outcomes of "diabetes-friendly" vs "diabetes-unfriendly" β-blockers in older nursing home residents with diabetes after acute myocardial infarction.. 20:2724-2732. 2018
- Baseline characteristics and enrichment results from the SONAR trial.. 20:1829-1835. 2018
- Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics.. 20:2014-2018. 2018
- Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.. 20:1369-1376. 2018
- Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years.. 18:820-8. 2016
- Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study.. 16:1265-8. 2014